Vaccine News and Research

Latest Vaccine News and Research

AFFiRiS AG develops PD01 vaccine for Parkinson's disease

Today AFFiRiS AG announced an important step forward in the development of its vaccine for Parkinson's disease. The vaccine, known as PD01, has undergone numerous preclinical tests which have confirmed its principle of action ("Proof of Concept").

31 Mar 2010

Renewed set of national policy guidelines to control diarrhoeal disease in Kenya

Today the Ministry of Public Health and Sanitation, together with the Department of Family Health (Division of Child and Adolescent Health), unveiled a renewed set of national policy guidelines to redouble diarrhoeal disease management and control efforts by putting proven interventions to work within the country's health system.

31 Mar 2010

Sanofi Pasteur accelerates deployment of Intercim's Pertinence Suite MOM software solution

Intercim, announces that Sanofi Pasteur, the vaccines division of the Sanofi-aventis Group, is accelerating the use of Pertinence Suite, Manufacturing Operations Management (MOM) software solution, within the European and North American sites of the worldwide leader of vaccines.

31 Mar 2010

Prevalence of head and neck cancer linked to human papillomavirus

Rates of oropharangeal cancer have increased by around 50 per cent in the last 20 years, according to a report in the British Medical Journal.

31 Mar 2010

CDC, Surgeon General report on increased number of H1N1 cases in southeast U.S.

Although H1N1 (swine flu) "has waned across much of the United States, the southeast is reporting an increase in cases of the H1N1 virus, U.S. health officials said on Monday," Reuters reports.

31 Mar 2010

BioSante Pharmaceuticals completes Azur Pharma Elestrin royalty buydown

BioSante Pharmaceuticals, Inc. today announced the successful completion of the Azur Pharma Elestrin royalty buydown, and financial results for the year ended December 31, 2009.

31 Mar 2010

YM BioSciences receives approval to expand enrolment in Phase I/II clinical trial of CYT387

YM BioSciences Inc., announced that it has received ethics board approval to expand enrolment in its Phase I/II clinical trial of CYT387 at Mayo Clinic in patients with myelofibrosis, a chronic debilitating condition, where patient's bone marrow is replaced by scar tissue.

31 Mar 2010

FDA allows GeoVax Labs to commence phase 1 clinical trial for HIV/AIDS therapeutic vaccine

GeoVax Labs, Inc., a biotechnology company that creates, develops, and tests innovative HIV/AIDS vaccines, is now allowed by the FDA to begin a phase 1 clinical trial for GeoVax's therapeutic vaccine, which is intended as a treatment for individuals infected with HIV. The company will begin a non-blinded study in HIV infected individuals who started drug treatment during their first year of infection.

30 Mar 2010

CTRC initiates patient enrolment in U.S. Phase 2 clinical trial of REOLYSIN

Oncolytics Biotech Inc. announced today that the Cancer Therapy & Research Center at the University of Texas Health Science Center has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with carboplatin and paclitaxel in patients with squamous cell carcinoma of the lungs.

30 Mar 2010

Savient Pharmaceuticals' resubmission of BLA for KRYSTEXXA accepted for FDA review

Savient Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has acknowledged receipt of and accepted for review the March 15, 2010 resubmission of the Biologics License Application for KRYSTEXXA™ (pegloticase), a treatment for chronic gout in patients refractory to conventional therapy.

30 Mar 2010

Resurgence of mumps orchitis among teenage boys and young men

Urologists at a leading Irish hospital have reported an alarming increase in the number of teenage boys and young men developing mumps orchitis, in a paper published in the April issue of the urology journal BJUI.

30 Mar 2010

Emory Institute of Drug Discovery and Zirus collaborate to develop new anti-viral drugs

The Emory Institute of Drug Discovery and Zirus, Inc., a biotechnology company based in Buford, Georgia, have entered into a collaboration and research agreement to develop novel compounds to treat infectious disease. Zirus uses a proprietary method for identifying genes and gene products in host cells that, when blocked, can prevent viruses from multiplying. Over the past several years, either alone or in collaboration with partners, including the Centers for Disease Control and Prevention (CDC), Zirus has identified, licensed and filed patents on more than 1000 targets.

30 Mar 2010

Decision Resources: Only 52.2% of first-line Alzheimer's disease patients prescribed AChEI

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that while approximately 70 percent of surveyed physicians' newly diagnosed patients have mild-to-moderate Alzheimer's disease, only 52.2 percent of first-line patients are prescribed an acetylcholinesterase inhibitor.

30 Mar 2010

Wall Street journal examines fundraising efforts by GAVI, Global Fund

The GAVI Alliance and the Global Fund to Fight AIDS, Tuberculosis and Malaria "on Friday began an effort to raise as much as $24 billion from members of the Group of 20 nations that will test whether a major push begun a decade ago against infectious diseases can survive the global recession," the Wall Street Journal reports. The two groups held meetings last week in The Hague with government representatives from existing and potential donor nations, according to the newspaper.

30 Mar 2010

Preclinical study of DAS181 for treatment and prevention of ILI published

NexBio, Inc. announced today the publication in the Journal of Infectious Diseases of a preclinical study suggesting that treatment with DAS181 (Fludase®) may reduce the risk of secondary bacterial pneumonia following influenza virus infection.

30 Mar 2010

GenVec announces discontinuation of TNFerade PACT trial for pancreatic cancer

GenVec, Inc. announced today that it is discontinuing its Phase 3 clinical trial of TNFerade™ in patients with locally advanced pancreatic cancer based on results of an interim analysis. This interim analysis of overall survival, conducted after the 184th death (two-thirds of total expected events), was designed to determine whether the study should continue.

30 Mar 2010

Also in Global Health News: H1N1; USAID's Global Pulse; Rotavirus vaccine; Uzbek doctors; Zimbabwe development; Malaria vaccine

WHO flu chief Keiji Fukuda on Monday announced that a group of 29 independent scientists and public health experts has been formed to evaluate the response of the organization and national governments to the emergence of H1N1 (swine flu), the Associated Press reports. According to Fukuda, the committee will hold its first meeting April 12-14 (3/29).

29 Mar 2010

GSK offers free vaccines for low income adults without insurance coverage

GlaxoSmithKline today announced the launch of the GSK Vaccines Access Program, which will provide the company's adult vaccines free of charge to eligible, low income individuals who do not have insurance coverage for vaccines. The program will cover the company's FDA-approved vaccines for Hepatitis A, Hepatitis B, tetanus, diphtheria, and pertussis for eligible persons ages 19 and older.

29 Mar 2010

Interim data comparing Cervista HPV HR to Hybrid Capture 2 presented at 4th Biennial Meeting of AOGIN

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that interim data from the first large-scale independent evaluation of clinical performance of Cervista® HPV HR compared to Hybrid Capture 2 (hc2), were presented at the 4th Biennial Meeting of AOGIN (Asia-Oceanic Research Organization in Genital Infection and Neoplasia) in New Delhi, India on March 26-28, 2010.

29 Mar 2010

Final results from Novavax' Phase II clinical trial of trivalent seasonal influenza VLP vaccine announced

Novavax, Inc. a clinical-stage vaccine company, released the final results from a Phase II clinical trial evaluating Novavax's trivalent seasonal influenza Virus-like particle (VLP) vaccine candidate in healthy adults. The study enrolled healthy volunteers 18 to 49 years in age who were immunized with a single injection of Novavax's trivalent seasonal influenza VLP vaccine matched to the influenza strains recommended for the 2008-2009 influenza vaccine.

29 Mar 2010

Vaccine News and Research

Latest Vaccine News and Research

AFFiRiS AG develops PD01 vaccine for Parkinson's disease

Renewed set of national policy guidelines to control diarrhoeal disease in Kenya

Sanofi Pasteur accelerates deployment of Intercim's Pertinence Suite MOM software solution

Prevalence of head and neck cancer linked to human papillomavirus

CDC, Surgeon General report on increased number of H1N1 cases in southeast U.S.

BioSante Pharmaceuticals completes Azur Pharma Elestrin royalty buydown

YM BioSciences receives approval to expand enrolment in Phase I/II clinical trial of CYT387

FDA allows GeoVax Labs to commence phase 1 clinical trial for HIV/AIDS therapeutic vaccine

CTRC initiates patient enrolment in U.S. Phase 2 clinical trial of REOLYSIN

Savient Pharmaceuticals' resubmission of BLA for KRYSTEXXA accepted for FDA review

Resurgence of mumps orchitis among teenage boys and young men

Emory Institute of Drug Discovery and Zirus collaborate to develop new anti-viral drugs

Decision Resources: Only 52.2% of first-line Alzheimer's disease patients prescribed AChEI

Wall Street journal examines fundraising efforts by GAVI, Global Fund

Preclinical study of DAS181 for treatment and prevention of ILI published

GenVec announces discontinuation of TNFerade PACT trial for pancreatic cancer

Also in Global Health News: H1N1; USAID's Global Pulse; Rotavirus vaccine; Uzbek doctors; Zimbabwe development; Malaria vaccine

GSK offers free vaccines for low income adults without insurance coverage

Interim data comparing Cervista HPV HR to Hybrid Capture 2 presented at 4th Biennial Meeting of AOGIN

Final results from Novavax' Phase II clinical trial of trivalent seasonal influenza VLP vaccine announced

Event guide: The 5th mRNA-Based Therapeutics Summit Europe eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Vaccine News and Research

Latest Vaccine News and Research

Event guide: The 5th mRNA-Based Therapeutics Summit Europe eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in